Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Wu
    Wu
  10. Wolden
    Wolden

Groups

  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)
  7. Center for Hematologic Malignancies (1674)
  8. Hematologic Malignancies, Division of (1609)
  9. Gynecology Disease Management Team (1425)
  10. Sloan Kettering Institute Faculty (1413)
Search Within
Formats
  1. Journal Article (7387)
  2. Meeting Abstract (4694)
  3. Review (616)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Real-world patient profile and step-up dosing process of early initiators of teclistamab for multiple myeloma (MM) in a hospital setting in the US: Premier Healthcare Database study
    Meeting Abstract

    Tan, C. R.; Chinaeke, E.; Kim, N.; Hester, L.; Fowler, J.; Gifkins, D.; Lin, D.; Walker, S.; Fu, A. Z.; Wu, B.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy outcomes and characteristics of patients with multiple myeloma (mm) who achieved sustained minimal residual disease negativity after treatment with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1
    Meeting Abstract

    Munshi, N.; Pavia, B.; Martin, T.; Usmani, S.; Lin, Y.; Schecter, J.; Jackson, C.; Madduri, D.; Zudaire, E.; Yeh, T. M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant (ASCT)
    Meeting Abstract

    Foley, N.; Russler-Germain, D.; Watkins, M.; Jacobsen, E.; Moskowitz, A.; Cashen, A.; Fehniger, T.; Kahl, B.; Bartlett, N.; Ghobadi, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Durability of responses with biweekly dosing of teclistamab in patients with relapsed/refractory multiple myeloma achieving a clinical response in the MajesTEC-1 study
    Meeting Abstract

    Usmani, S. Z.; Karlin, L.; Benboubker, L.; Nahi, H.; San-Miguel, J.; Trancucci, D.; Qi, K.; Stephenson, T.; Puchalt, A. P.; Chastain, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save